Multiple primary malignancies involving lung cancer: a single-center experience

Abstract

Objective: Currently, unlike earlier years, patients affected by multiple primary malignancies (MPM) are significantly increased, thus representing a clinical-pathologic category worthy of attention. Their clinical features and prognosis still need to be studied thoroughly, and this is the aim of our study. Methods: Patients with MPM involving lung cancer admitted in our center between January 2006 and December 2016 were considered. Parametric and nonparametric testing was used for statistical comparisons. Univariate and multivariate analysis was used to evaluate the variables associated with a prognostic value. Results: MPM incidence was 19.8%. Among the 222 patients with MPM enrolled, 204 (91.8%) had two malignancies, while 18 (8.2%) had three malignancies, 38 (17.1%) were synchronous, 41 (18.5%) had lung cancer first (LCF) and 181 (81.5%) had other cancer first (OCF). A significant difference between the time of first cancer diagnosis to the second cancer diagnosis in the LCF vs OCF group was found (median 32 vs 51 months; p-value: 0.038). The most frequent anatomical sites of malignancies preceding or following lung cancer were prostate, colorectal, bladder, and larynx. Multivariate analysis revealed that sex, histologic pattern, and time and order of occurrence were independent factors for overall survival, with male sex, squamous cell lung carcinoma, synchronous and LCF MPM significantly associated with poorer overall survival. Conclusions: Prostate, colorectal, bladder, and larynx were the most frequent anatomical sites of malignancies preceding or following lung cancer. Male sex, squamous cell lung carcinoma, synchronous and LCF MPM might be associated with poorer prognosis.

Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database

“…In our cohort of patients, we noticed a relatively high incidence of previous cancers (38.9%) 22 . We investigated these data among different institutions, but no clear explanation could be drawn.…”

“…In our cohort of patients, we noticed a relatively high incidence of previous cancers (38.9%). 22 We investigated these data among different institutions, but no clear explanation could be drawn. We can speculate that this relative incidence of previous cancers might be explained with a more careful follow-up ruled out in these patients compared to the general population.…”

Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study

“…Moreover, breast adenocarcinoma, lung cancer and prostate adenocarcinoma accounted for the most represented PC; these data are in line with those reported by Song and colleagues [ 16 ] based on the Surveillance, Epidemiology and End Results database. Conversely, Liu et al [ 17 ] and Donin et al [ 18 ] found a higher proportion of cancers from the upper aerodigestive tract, whereas Ventura et al [ 9 ] reported a higher incidence of cancers from the urogenital system.…”

“…A population-based study [ 8 ] reported that lung cancer was the most frequently diagnosed second primary cancer among cancer survivors in the USA. A frequency of up to 22% has been described so far [ 9 ], but the exact percentage of patients with multiple cancers varies widely because the different reports based their selection of patients and their surveillance protocol on the type of cancer and on the respective reimbursement systems of each national health system. Moreover, differences in ethnicity in the analysed cohort of patients also have a strong influence on the epidemiology of cancers [ 10 ].…”

Metachronous Multiple Primary Carcinoma With Acute Promyelocytic Leukemia: 2 Cases Report and Literature Review

“…The prognosis of multiple primary cancers is influenced by a number of factors, including the chronological nature of tumorigenesis ( 24 ). In a study by Ventura ( 25 ) on patients with lung cancer combined with other solid tumors, it was shown that patients with heterochronic multiple primary cancers had a higher risk of death than those with simultaneous multiple primary cancers. This may be due to the weakening of the body’s immune function as a result of receiving multiple anti-tumor treatments within a short period of time or at the same time.…”